Press release from Companies

Publicerat: 2020-12-04 09:00:00

DanCann Pharma A/S: DanCann Pharma A/S: The United Nations’ commission reclassifies cannabis, no longer considered risky narcotic

The United Nations (UN) removes cannabis from list of most dangerous drugs following a recommendation from the World Health Organization (WHO), the United Nations’ Commission for Narcotic Drugs voted Wednesday to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs, a decision that is expected to eventually have a far-reaching impact on cannabis and cannabinoid research and for medical use and purposes worldwide.

Since 1961, cannabis has been classified as one the most dangerous drugs in the world. This has prevented companies from working within R&D and/or to produce medical cannabis products and prevented many patients from treatment with cannabis.

The UN Commission for Narcotic Drugs includes 53 member states, and the vote on cannabis reclassification was very close, passing by a 27 to 25 margin. Prior to Wednesday’s vote, cannabis had been listed alongside drugs such as heroin, methadone, and morphine.

CEO, Mr. Jeppe Krog Rasmussen, comments:

>First, a huge victory for patients all over the world and another step in the right direction in terms of treatment with medical cannabis. With the reclassification of cannabis, we expect to see an accelerating of the legalization wave - and thereby promote growth within our business area. This will unimaginably make our work across nations far more painless - and the whole business development hereof.

We hope that this opens up new doors for patients and their access to medical cannabis and cannabinoid treatment on a global scale - and especially a strong indication around our core markets where European nations were among those who voted in favor.<

For more information, visit: https://news.un.org/en/


About DanCann Pharma

DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Website: www.dancann.com

Läs mer hos Cision
Läs mer om DanCann Pharma A/S